vTv Therapeutics to Participate in Upcoming Investor Conferences
vTv Therapeutics (Nasdaq: VTVT) said management will participate in two investor conferences in late February and early March 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
vTv Therapeutics (Nasdaq: VTVT) said management will participate in two investor conferences in late February and early March 2026. Events: Oppenheimer 36th Annual Healthcare Life Sciences Conference (Feb 26, 2026, 11:20 AM ET, virtual, presentation only) and TD Cowen 46th Annual Health Care Conference (Mar 3, 2026, 9:50 AM ET, Boston, presentation and 1x1 meetings). Webcasts will be available for both events per the company.
Details
News Market Reaction – VTVT
On Feb 13, the day this news came out, VTVT closed 7.18% below the previous close.
Data tracked by StockTitan Argus for the Feb 13 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following upcoming investor conferences:
Oppenheimer 36th Annual Healthcare Life Sciences Conference
Date: Thursday, February 26, 2026
Time: 11:20 AM ET
Format: Presentation Only
Location: Virtual
Webcast Link
TD Cowen 46th Annual Health Care Conference
Date: Tuesday, March 3, 2026
Time: 9:50 AM ET
Format: Presentation and 1x1 Meetings
Location: Boston, MA
Webcast Link
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.